Cancers, Vol. 12, Pages 2283: Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study

Conclusions: pembrolizumab showed no apparent benefit in these patients. No molecular biomarker was found to be associated with pembrolizumab activity.

Source: Cancers - August 13, 2020 Category: Cancer & Oncology Authors: Giuseppe Lombardi Valeria Barresi Stefano Indraccolo Michele Simbolo Matteo Fassan Susanna Mandruzzato Matteo Simonelli Mario Caccese Marco Pizzi Arianna Fassina Marta Padovan Elena Masetto Marina Paola Gardiman Maria Giuseppina Bonavina Maria Caffo Pasqu Tags: Article Source Type: research